The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Mesenchymal Stem Cells for Bronchopulmonary Dysplasia: Phase 1 Dose-Escalation Clinical Trial
Open accessAbstract
OBJECTIVE: To assess the safety and feasibility of allogeneic human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation in preterm infants. STUDY DESIGN: In a phase I dose-escalation trial, we assessed the safety and feasibility of a single, intratracheal transplantation of hUCB-derived MSCs in preterm infants at high risk for bronchopulmonary dysplasia (BPD). The first 3 patients were given a low dose (1 × 10(7) cells/kg) of cells, and the next 6 patients were given a high dose (2 × 10(7) cells/kg). We compared their adverse outcomes, including BPD severity, with those of historical case-matched comparison group. RESULTS: Intratracheal MSC transplantation was performed in 9 preterm infants, with a mean gestational age of 25.3 ± 0.9 weeks and a mean birth weight of 793 ± 127 g, at a mean of 10.4 ± 2.6 days after birth. The treatments were well tolerated, without serious adverse effects or dose-limiting toxicity attributable to the transplantation. Levels of interleukin-6, interleukin-8, matrix metalloproteinase-9, tumor necrosis factor α, and transforming growth factor β1 in tracheal aspirates at day 7 were significantly reduced compared with those at baseline or at day 3 posttransplantation. BPD severity was lower in the transplant recipients, and rates of other adverse outcomes did not differ between the comparison group and transplant recipients. CONCLUSION: Intratracheal transplantation of allogeneic hUCB-derived MSCs in preterm infants is safe and feasible, and warrants a larger and controlled phase II study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Papile, L.-A., Burstein, J., Burstein, R., & Koffler, H. (1978) · The Journal of Pediatrics · doi:10.1016/s0022-3476(78)80282-0 · Cited by 6,430
JOBE, A. H., & BANCALARI, E. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.7.2011060 · Cited by 4,795
Neonatal Necrotizing Enterocolitis: Therapeutic Decisions Based upon Clinical Staging
BELL, M. J., TERNBERG, J. L., FEIGIN, R. D., KEATING, J. P., MARSHALL, R., BARTON, L., & BROTHERTON, T. (1978) · Annals of Surgery · doi:10.1097/00000658-197801000-00001 · Cited by 3,514
Neonatal Outcomes of Extremely Preterm Infants From the NICHD Neonatal Research Network
Stoll, B. J., Hansen, N. I., Bell, E. F., Shankaran, S., Laptook, A. R., Walsh, M. C., Hale, E. C., Newman, N. S., Schibler, K., Carlo, W. A., et al. (2010) · Pediatrics · doi:10.1542/peds.2009-2959 · Cited by 2,731
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593
Is Chronic Lung Disease in Low Birth Weight Infants Preventable? A Survey of Eight Centers
Avery, M. E., Tooley, W. H., Keller, J. B., Hurd, S. S., Bryan, M. H., Cotton, R. B., Epstein, M. F., Fitzhardinge, P. M., Hansen, C. B., Hansen, T. N., et al. (1987) · Pediatrics · doi:10.1542/peds.79.1.26 · Cited by 875
The new bronchopulmonary dysplasia
Jobe, A. H. (2011) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e3283423e6b · Cited by 576
Immunomodulatory effects of fetal and adult mesenchymal stem cells
Le Blanc, K. (2003) · Cytotherapy · doi:10.1080/14653240310003611 · Cited by 514
Bone Marrow Stromal Cells Attenuate Lung Injury in a Murine Model of Neonatal Chronic Lung Disease
Aslam, M., Baveja, R., Liang, O. D., Fernandez-Gonzalez, A., Lee, C., Mitsialis, S. A., & Kourembanas, S. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200902-0242oc · Cited by 508
Aaberg, T. (1987) · Archives of Ophthalmology · doi:10.1001/archopht.1987.01060070042025 · Cited by 476
Cited by
Stem Cell Therapies in Clinical Trials: Progress and Challenges
Trounson, A., & McDonald, C. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.06.007 · Cited by 1,468
Stem cell-based therapy for human diseases
Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01134-4 · Cited by 1,074
Thébaud, B., Goss, K. N., Laughon, M., Whitsett, J. A., Abman, S. H., Steinhorn, R. H., Aschner, J. L., Davis, P. G., McGrath-Morrow, S. A., Soll, R. F., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0127-7 · Cited by 1,070
Bronchopulmonary Dysplasia: Executive Summary of a Workshop
Higgins, R. D., Jobe, A. H., Koso-Thomas, M., Bancalari, E., Viscardi, R. M., Hartert, T. V., Ryan, R. M., Kallapur, S. G., Steinhorn, R. H., Konduri, G. G., et al. (2018) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2018.01.043 · Cited by 956
Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial
Wilson, J. G., Liu, K. D., Zhuo, H., Caballero, L., McMillan, M., Fang, X., Cosgrove, K., Vojnik, R., Calfee, C. S., Lee, J.-W., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70291-7 · Cited by 759
Metadata
- Authors
- Chang, Y. S., Ahn, S. Y., Yoo, H. S., Sung, S. I., Choi, S. J., Oh, W. I., & Park, W. S.
- Venue
- The Journal of Pediatrics
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 164
- Issue
- 5
- Pages
- 966-972.e6
- ISSN
- 0022-3476 (ISSN-L)
- OpenAlex
- W2005962589
- Cited by
- 455
- References
- 24
- FWCI
- 30.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal Stem Cells for Bronchopulmonary Dysplasia: Phase 1 Dose-Escalation Clinical Trial. https://app.cochat.ai/papers/10.1016/j.jpeds.2013.12.011
- The paper
- Chang, Y. S., Ahn, S. Y., Yoo, H. S., Sung, S. I., Choi, S. J., Oh, W. I., & Park, W. S. (2014). Mesenchymal Stem Cells for Bronchopulmonary Dysplasia: Phase 1 Dose-Escalation Clinical Trial. The Journal of Pediatrics. https://doi.org/10.1016/j.jpeds.2013.12.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.